Canaccord Genuity Group maintains "Buy" rating for Intellia Therapeutics (NASDAQ:NTLA) at $73.00 price target.
Canaccord Genuity Group reaffirms "Buy" rating for Intellia Therapeutics (NASDAQ:NTLA) with a $73.00 price target, while other analysts have issued mixed opinions on the stock. StockNews.com upgraded NTLA to a sell rating, while Truist Financial and Cantor Fitzgerald maintained a buy and overweight rating, respectively. Wedbush reissued a neutral rating, and Citigroup lowered its rating to neutral with a target price of $29.00. BMO Capital Markets boosted its rating to outperform with a $70.00 price target.
June 30, 2024
3 Articles